| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Applied Pharmacology Section, Laboratory of Medicinal Chemistry and Pharmacology, National Cancer Institute, Bethesda, Maryland 20205
The antiproliferative effect of human fibroblast interferon (IFN-ß), human recombinant leukocyte interferon (IFN-
A), and polyinosinic·polycytidylic acid [poly(I)·poly(C)] was investigated in human colon carcinoma cell line HT-29. Exposure of HT-29 cells for 1 to 3 days with 100 to 2000 units of either interferon preparation resulted in a 30 to 50% inhibition of growth after 3 days. Similar treatment of cells with 100 µg per ml poly(I)·poly(C) resulted in progressive inhibition of growth by 50 to 60% in 2 to 3 days. The inhibitory effects of combination of either IFN-ß or IFN-
A with poly(I)·poly(C) were additive with up to 80 to 90% inhibition of cell growth after 3 days of exposure. None of the treatment regimens was markedly cytocidal, and only 25 to 30% reduction in colony formation was noted under optimal treatment conditions following 2 to 3 days of drug exposure. Measurements of DNA, RNA, and protein synthesis following interferon treatment indicated a dose-dependent reduction in all three parameters, particularly when interferon was administered with poly(I)·poly(C). The associated changes in the (2',5')oligoadenylate [(2',5')oligo(A)] pathway produced by IFN-ß and IFL-
A were measured under growth-inhibitory conditions. A concentration-dependent induction of (2',5')oligo(A) synthetase was produced by IFN-ß or IFL-
A with a concomitant decrease in (2',5')oligo(A) phosphodiesterase. Poly(I)·poly(C) alone induced (2',5')oligo(A) synthetase activity but had no effect on the associated activity of phosphodiesterase. The combination of either IFN-ß or IFL-
A and poly(I)·poly(C) further reduced (2',5')oligo(A) phosphodiesterase activity. There was no general dose-response correlation between the induction of (2',5')oligo(A) synthetase and the cytostatic activity of interferon treatment alone or in combination with double-stranded RNA.
1 To whom requests for reprints should be addressed, at National Cancer Institute, Building 37, Room 6D28, Bethesda, Md. 20205.
Received 8/ 6/82. Accepted 3/ 9/83.
This article has been cited by other articles:
![]() |
L. R. SAUNDERS and G. N. BARBER The dsRNA binding protein family: critical roles, diverse cellular functions FASEB J, June 1, 2003; 17(9): 961 - 983. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |